In connection with the start of the phase 3 trials of PCV21, Sanofi has expanded its alliance with South Korea-based SK Bio, ...

Respiratory virus season has arrived, and hopefully you’re up to date on vaccinations that can help prevent infectious diseases including COVID, the flu, whooping cough, and respiratory syncytial ...

SK bioscience and Sanofi have expanded their agreement to jointly develop pneumococcal conjugate vaccines (PCVs) targeting ...

The following is a summary of “Evaluating Sex Differences in Pneumococcal Disease Burden and Vaccination Effectiveness in Adults: A Population-Based Study,” published in the December 2024 issue of ...

SNY begins phase III study for its 21-valent pneumococcal conjugate vaccine for treating invasive pneumococcal disease in ...

In addition to increasing vaccine coverage in older adults, they need to monitor the changing epidemiology of pneumococcal serotypes causing invasive disease. [134] In the face of these changes ...

SK Bioscience, Sanofi collaborate on next-gen pneumococcal vaccine development SK Bioscience and Sanofi join forces to ...

Goldman Sachs analyst maintains Buy rating on Pfizer with $33 price target. Discusses update on 2nd-gen C. diff vaccine in ...

French pharma major Sanofi says it has entered into a new chapter of the collaboration with South Korean firm SK bioscience in pneumococcal vaccines, with an expanded agreement to develop, license and ...

Anticipated growth for ‘Saudi Arabia 23 Valent Pneumococcal Polysaccharide Vaccine Market’ is significant from 2024 to 2032. The market showed steady growth in 2024 and is expected to continue rising ...